secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2022-11-21T23:59:59+00:00
Accession:  0001213900-22-074266
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q3 2022 sales down 7% YoY, net loss of $655K vs prior-year profit; margins hurt by contamination
--------------------------------------------------------------------------------

- Q3 2022 product sales of $4.80M, down 7% from $5.15M in Q3 2021; nine-month sales up 6% to $14.66M.
- Net loss of $655K ($0.08/share) in Q3 vs net income of $148K ($0.02/share) a year ago; nine-month net loss $826K.
- Gross margin fell to 38% in Q3 from 47% in prior year due to product contamination events causing inventory write-offs.
- Restated Q1 and Q2 2022 filings to accrue $222K of deferred compensation (PTO); no cash impact.
- FDA submission for Re-Tain CMC Technical Section on track for Q1 2023, subject to six-month review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390022074266/0001213900-22-074266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390022074266/ea169099-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-074266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer